Concord Biotech Ltd

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in price momentum and technical indicators, signalling a transition from a mildly bearish trend to a sideways movement. Despite a robust day gain of 3.24%, the stock’s technical landscape presents a complex picture, with mixed signals from MACD, RSI, moving averages, and other key indicators.

The Sensex climbed 1.25% on 29 Apr 2026, yet Concord Biotech Ltd outpaced both the benchmark and its sector with a robust 7.12% gain, touching an intraday high of Rs 1152.3. That 7.02-percentage-point outperformance signals a distinctly stock-specific rally rather than a mere market tailwind.

Concord Biotech Ltd’s investment rating has been upgraded from Strong Sell to Sell as of 24 April 2026, reflecting nuanced shifts across technical indicators and financial performance metrics. Despite persistent challenges in profitability and valuation concerns, improvements in technical trends and management efficiency have moderated the outlook, prompting a recalibration of the stock’s rating within the Pharmaceuticals & Biotechnology sector.

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook. Despite this slight improvement, the stock continues to face significant downward pressure, reflected in its recent price action and technical indicators.

Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This transition is underscored by deteriorating technical indicators including MACD, moving averages, and Bollinger Bands, signalling increased selling pressure and subdued investor sentiment.

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action and technical parameters suggest increasing downside risks amid broader market pressures and sector-specific challenges.

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 13 April 2026. This revision reflects deteriorating technical indicators, subdued financial trends, expensive valuation metrics, and concerns over the company’s overall quality. The downgrade comes amid a challenging market environment and disappointing recent quarterly results, signalling caution for investors.

Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 April 2026, providing investors with the latest insights into its performance and outlook.

Concord Biotech Ltd’s investment rating has been upgraded from Strong Sell to Sell as of 6 April 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The pharmaceutical and biotechnology company’s overall Mojo Score now stands at 34.0, reflecting a cautious but slightly improved outlook amid persistent operational headwinds and valuation concerns.

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook. Despite this slight improvement, the stock continues to face significant headwinds, reflected in its recent price action and technical indicators, underscoring ongoing challenges for investors navigating its current trajectory.

Concord Biotech Ltd’s stock price declined sharply to hit a new 52-week low of ₹987.05 on 2 April 2026, marking a significant milestone in its ongoing downward trajectory. This drop comes despite a brief two-day rally, as the stock underperformed its sector and broader market indices amid persistent financial headwinds.

For the fifth straight session, Concord Biotech Ltd closed lower, breaching its 52-week low at Rs 990 on 30 Mar 2026, marking a significant decline from its 52-week high of Rs 2,149.9. This persistent downtrend has dragged the stock down by 38.54% over the past year, considerably underperforming the Sensex, which itself is down 6.33% in the same period.

Concord Biotech Ltd’s stock price declined sharply to a new 52-week low of Rs.996 on 27 March 2026, marking a significant drop amid broader market weakness and company-specific performance concerns. The stock underperformed its sector and key moving averages, reflecting ongoing challenges in financial metrics and market sentiment.

Concord Biotech Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 March 2026, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 27 March 2026, providing investors with the latest insights into its performance and valuation.

For the fifth straight session, Concord Biotech Ltd closed lower, breaching its 52-week low at Rs 1,045.9 on 23 Mar 2026. This marks a significant decline amid a broader market downturn, with the stock falling 8.07% over the last three days alone.